An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

Summary

An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.

Timeline

Start

2026-06-01

Primary completion

2030-01-01

Completion

2030-01-31

Publications

• Background Angelos MG, Ballard HJ, Barta SK. Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. J Pers Med. 2022 Feb 11;12(2):267. doi: 10.3390/jpm12020267.
• Background Foley NC, Mehta-Shah N. Management of Peripheral T-cell Lymphomas and the Role of Transplant. Curr Oncol Rep. 2022 Nov;24(11):1489-1499. doi: 10.1007/s11912-022-01310-3. Epub 2022 Aug 10.

Drugs

Indications